Baird Financial Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.4M | Buy |
468,115
+22,193
| +5% | +$1.29M | 0.04% | 283 |
|
|
2025
Q4 | $24.1M | Sell |
445,922
-12,954
| -3% | -$623K | 0.04% | 327 |
|
|
2025
Q3 | $20.7M | Sell |
458,876
-73,241
| -14% | -$3.42M | 0.03% | 370 |
|
|
2025
Q2 | $24.6M | Sell |
532,117
-762
| -0.1% | -$37.4K | 0.04% | 320 |
|
|
2025
Q1 | $32.5M | Buy |
532,879
+26,478
| +5% | +$1.54M | 0.06% | 248 |
|
|
2024
Q4 | $28.6M | Sell |
506,401
-39,146
| -7% | -$2.19M | 0.05% | 274 |
|
|
2024
Q3 | $28.2M | Sell |
545,547
-28,703
| -5% | -$1.35M | 0.05% | 283 |
|
|
2024
Q2 | $23.8M | Sell |
574,250
-272,404
| -32% | -$12.2M | 0.05% | 288 |
|
|
2024
Q1 | $45.9M | Sell |
846,654
-57,512
| -6% | -$2.93M | 0.1% | 211 |
|
|
2023
Q4 | $46.4M | Sell |
904,166
-159,405
| -15% | -$8.37M | 0.11% | 203 |
|
|
2023
Q3 | $61.7M | Buy |
1,063,571
+12,598
| +1% | +$772K | 0.17% | 142 |
|
|
2023
Q2 | $67.2M | Sell |
1,050,973
-40,112
| -4% | -$2.69M | 0.18% | 136 |
|
|
2023
Q1 | $75.6M | Sell |
1,091,085
-4,270
| -0.4% | -$301K | 0.19% | 128 |
|
|
2022
Q4 | $78.8M | Buy |
1,095,355
+51,595
| +5% | +$3.89M | 0.21% | 107 |
|
|
2022
Q3 | $74.2M | Sell |
1,043,760
-25
| -0% | -$1.81K | 0.22% | 111 |
|
|
2022
Q2 | $80.4M | Sell |
1,043,785
-231,590
| -18% | -$17.6M | 0.22% | 100 |
|
|
2022
Q1 | $93.1M | Sell |
1,275,375
-58,254
| -4% | -$3.91M | 0.23% | 93 |
|
|
2021
Q4 | $83.2M | Sell |
1,333,629
-195,439
| -13% | -$11.5M | 0.19% | 124 |
|
|
2021
Q3 | $90.5M | Buy |
1,529,068
+65,023
| +4% | +$4.28M | 0.23% | 101 |
|
|
2021
Q2 | $97.8M | Buy |
1,464,045
+5,048
| +0.3% | +$329K | 0.25% | 91 |
|
|
2021
Q1 | $92.1M | Buy |
1,458,997
+77,949
| +6% | +$4.85M | 0.26% | 90 |
|
|
2020
Q4 | $85.7M | Buy |
1,381,048
+69,944
| +5% | +$4.3M | 0.26% | 97 |
|
|
2020
Q3 | $79M | Buy |
1,311,104
+145,976
| +13% | +$8.79M | 0.27% | 88 |
|
|
2020
Q2 | $67.7M | Buy |
1,165,128
+36,784
| +3% | +$2.2M | 0.26% | 97 |
|
|
2020
Q1 | $62.9M | Buy |
1,128,344
+67,240
| +6% | +$4.11M | 0.29% | 75 |
|
|
2019
Q4 | $68.1M | Buy |
1,061,104
+109,960
| +12% | +$6.3M | 0.24% | 110 |
|
|
2019
Q3 | $48.2M | Sell |
951,144
-108,636
| -10% | -$5.11M | 0.19% | 137 |
|
|
2019
Q2 | $48.1M | Buy |
1,059,780
+367,528
| +53% | +$17.1M | 0.19% | 139 |
|
|
2019
Q1 | $33M | Buy |
692,252
+104,220
| +18% | +$5.19M | 0.19% | 147 |
|
|
2018
Q4 | $30.6M | Sell |
588,032
-51,245
| -8% | -$2.75M | 0.21% | 133 |
|
|
2018
Q3 | $39.7M | Buy |
639,277
+428
| +0.1% | +$25.4K | 0.25% | 121 |
|
|
2018
Q2 | $35.4M | Buy |
638,849
+19,927
| +3% | +$1.08M | 0.24% | 123 |
|
|
2018
Q1 | $39.1M | Buy |
618,922
+15,542
| +3% | +$1,000K | 0.28% | 109 |
|
|
2017
Q4 | $37M | Buy |
603,380
+10,223
| +2% | +$639K | 0.26% | 120 |
|
|
2017
Q3 | $37.8M | Sell |
593,157
-77,510
| -12% | -$4.53M | 0.29% | 105 |
|
|
2017
Q2 | $37.4M | Buy |
670,667
+43,652
| +7% | +$2.38M | 0.29% | 110 |
|
|
2017
Q1 | $34.1M | Sell |
627,015
-45,371
| -7% | -$2.49M | 0.28% | 110 |
|
|
2016
Q4 | $39.3M | Buy |
672,386
+96,485
| +17% | +$5.27M | 0.34% | 79 |
|
|
2016
Q3 | $31.1M | Buy |
575,901
+174,317
| +43% | +$11.2M | 0.28% | 102 |
|
|
2016
Q2 | $29.9M | Buy |
401,584
+10,188
| +3% | +$720K | 0.27% | 107 |
|
|
2016
Q1 | $25M | Buy |
391,396
+4,972
| +1% | +$314K | 0.24% | 127 |
|
|
2015
Q4 | $26.6M | Buy |
386,424
+18,227
| +5% | +$1.2M | 0.27% | 106 |
|
|
2015
Q3 | $21.8M | Sell |
368,197
-2,092
| -0.6% | -$133K | 0.23% | 124 |
|
|
2015
Q2 | $24.6M | Buy |
+370,289
| New | +$24.4M | 0.24% | 123 |
|
Other funds holding BMY
VCM
VPM
Baird Financial Group's BMY Position: Q1 2026 in Review
Baird Financial Group increased its Bristol-Myers Squibb (BMY) stake by 5% in Q1 2026, buying an estimated $1.29M and bringing the position to 468,115 shares worth $28.4M. The position accounts for 0.04% of the portfolio, ranked #283.
Baird Financial Group first reported a position in BMY in Q2 2015 and has held it in 44 quarters since. The position peaked at $97.8M in Q2 2021. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Baird Financial Group held 468,115 shares of Bristol-Myers Squibb worth $28.4M as of Q1 2026.
- Baird Financial Group bought 22,193 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.29M.
- Bristol-Myers Squibb made up 0.04% of Baird Financial Group's portfolio in Q1 2026, its #283 holding.
- Baird Financial Group first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 44 quarters since.
- Baird Financial Group's Bristol-Myers Squibb position peaked at $97.8M in Q2 2021.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.